// App-Quantinova.ai

167 : Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases.

Researchers

Presenter

  • Hiroji Uemura

Principal Investigators

  • Yoshiaki Wakumoto

  • Hirotsugu Uemura

  • Go Kimura

  • Akira Yokomizo

  • Hiroaki Kikukawa

  • Atsushi Mizokami

  • Takeo Kosaka

  • Naoya Masumori

  • Yoshihide Kawasaki

  • Junji Yonese

  • Yasutomo Nasu

  • Satoshi Fukasawa

  • Takayuki Sugiyama

  • Motohide Uemura

  • Iku Yamaguchi

  • Hirokazu Tsutsui

  • Eisuke Matsunaga

  • Nobuaki Matsubara

Medical Centers

  • Department of Urology/Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan

  • Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan

  • Immunology, Juntendo University Hospital, Tokyo, Japan

  • Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan

  • Department of Urology, Nippon Medical School Hospital, Tokyo, Japan

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Department of Urology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan

  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

  • Tohoku University Graduate School of Medicine, Miyagi, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

  • Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan

  • Department of Neurosurgery, Yamagata University Faculty of Medicine, Yamagata, Japan

  • Department of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  • Clinical Statistics, Bayer Yakuhin, Ltd., Osaka, Japan

  • Clinical Development Specialty Medicine, Bayer Yakuhin, Ltd., Osaka, Japan

  • Medical Affairs Oncology & Hematology Medical Science Liaison, Bayer Yakuhin, Ltd., Osaka, Japan

  • Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Alkaline phosphatase

  • Prostate specific antigen

Drug/Treatment

  • Xofigo

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01929655

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved